Taysha Gene Therapies, Inc. (NASDAQ:TSHA) Stock Has Average Price Target of $12.77

Taysha Gene Therapies, Inc. (NASDAQ:TSHA) has earned a consensus recommendation of “Buy” from the fifteen brokerages that are covering the stock, Marketbeat reports. One analyst has rated the stock with a sell rating, twelve have given a buy rating and two have assigned a strong buy rating to the company. The average 1-year target price among brokerages that have issued a report on the stock in the last year is $12.77.

A number of equities analysts recently commented on TSHA shares. Weiss Ratings restated a “sell (d-)” rating on shares of Taysha Gene Therapies in a report on Monday, September 21st. Wolfe Research began coverage on shares of Taysha Gene Therapies in a research note on Thursday, September 17th. They issued an “outperform” rating for the company. Finally, The Goldman Sachs Group boosted their target price on shares of Taysha Gene Therapies from $11.00 to $13.00 and gave the stock a “buy” rating in a research report on Tuesday, July 21st.

Taysha Gene Therapies Price Performance

TSHA opened at $4.33 on Friday. The stock has a market cap of $1.41 billion, a price-to-earnings ratio of -10.31 and a beta of 1.36. Taysha Gene Therapies has a 1 year low of $3.45 and a 1 year high of $7.30. The company has a current ratio of 17.76, a quick ratio of 17.76 and a debt-to-equity ratio of 0.13. The stock has a fifty day moving average price of $4.63 and a 200 day moving average price of $5.29.

Taysha Gene Therapies (NASDAQ:TSHA) last issued its earnings results on Tuesday, August 11th. The company reported ($0.13) earnings per share for the quarter, missing the consensus estimate of ($0.11) by ($0.02). Analysts forecast that Taysha Gene Therapies will post -0.52 EPS for the current fiscal year.

Institutional Investors Weigh In On Taysha Gene Therapies

Several institutional investors and hedge funds have recently modified their holdings of TSHA. Russell Investments Group Ltd. boosted its holdings in shares of Taysha Gene Therapies by 21.8% during the 3rd quarter. Russell Investments Group Ltd. now owns 75,147 shares of the company’s stock worth $366,000 after buying an additional 13,442 shares during the period. Ethic Inc. lifted its position in shares of Taysha Gene Therapies by 117.2% during the 3rd quarter. Ethic Inc. now owns 27,182 shares of the company’s stock worth $132,000 after purchasing an additional 14,670 shares during the last quarter. Pictet Asset Management Holding SA boosted its stake in Taysha Gene Therapies by 19.6% during the 3rd quarter. Pictet Asset Management Holding SA now owns 3,313,062 shares of the company’s stock valued at $16,135,000 after purchasing an additional 542,361 shares during the period. Privium Fund Management B.V. boosted its stake in Taysha Gene Therapies by 17.1% during the 3rd quarter. Privium Fund Management B.V. now owns 232,900 shares of the company’s stock valued at $1,134,000 after purchasing an additional 34,000 shares during the period. Finally, Alps Advisors Inc. grew its holdings in Taysha Gene Therapies by 48.6% in the 3rd quarter. Alps Advisors Inc. now owns 431,669 shares of the company’s stock valued at $2,102,000 after buying an additional 141,126 shares during the last quarter. Institutional investors and hedge funds own 77.70% of the company’s stock.

About Taysha Gene Therapies

Taysha Gene Therapies, Inc is a clinical-stage biotechnology company focused on developing gene therapies for severe monogenic diseases of the central nervous system. The company uses adeno-associated virus (AAV) delivery technologies and other genetic medicine approaches to address disorders that currently have limited or no effective treatment options.

Taysha’s development programs have included TSHA-102 for Rett syndrome, TSHA-101 for GM1 gangliosidosis and TSHA-120 for giant axonal neuropathy.